February 11, 2015 / 12:37 PM / in 3 years

BUZZ-Oncolytics Biotech Inc: Lead drug gets orphan drug status

** Canadian biotech company’s U.S.-listed shares up 16.6 pct at 54 cents premarket

** Company says U.S. FDA grants its lead drug, reolysin, orphan drug status for the treatment of ovarian cancer

** Orphan designation is granted to drugs developed to treat rare diseases, offering the developer several incentives, including seven-year marketing exclusivity in the U.S.

** Reolysin is being tested for use in a plethora of cancers, both alone and in combination with chemotherapy

** Up to Tuesday’s close, U.S.-listed stock had lost nearly 34 pct of its value since Nov.6, when it posted a smaller-than-expected Q3 loss

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below